Table 1.
IBR2 analogues inhibit the growth of the triple-negative human breast cancer cell line MDA-MB-468.
| Cmpd. | IC50 (mM) | Cmpd. | IC50 (mM) | Cmpd. | IC50 (mM) |
|---|---|---|---|---|---|
| IBR2 (rac) | 14.8 | ||||
| IBR101 (R) | 11.7 | IBR109 (R) | 14.8 | IBR117 (R) | 9.5 |
| IBR102 (S) | 13.2 | IBR110 (S) | 16.7 | IBR118 (S) | 14.3 |
| IBR103 (R) | 12.7 | IBR111 (R) | 11.1 | IBR119 (S) | >25 |
| IBR104 (S) | 19.2 | IBR112 (S) | 22.2 | IBR120 (R) | 3.1 |
| IBR105 (R) | 14.2 | IBR113 (R) | 13.6 | IBR121 (S) | >12 |
| IBR106 (S) | 17.2 | IBR114 (S) | 20.7 | IBR122 (rac) | 12.7 |
| IBR107 (R) | 11.2 | IBR115 (R) | 14.7 | IBR123 (rac) | 6.3 |
| IBR108 (S) | 25.7 | IBR116 (S) | >50 | IBR124 (rac) | 6.2 |